These observations are of interest because they raise the possibility that human 2-oxoacid metabolites other than 2OG may be substrates of R140Q IDH2 and potentially other IDH1/2 variants in a cellular context and that active site–binding 2OG derivatives/mimics might be developed that are selective inhibitors of cancer-associated IDH1/2 variants. This evidence concerns the gene IDH2 and cancer.